Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

E. Cortes, Jörge; Talpaz, Moshe; Smith, Hedy; S. Snyder, David; Khoury, Jean; N. Bhalla, Kapil; Pinilla‐Ibarz, Javier; A. Larson, Richard; Mitchell, David; Wise, Scott; J. Rutkoski, Thomas; D. Smith, Bryan; L. Flynn, Daniel; M. Kantarjian, Hagop; Rosen, Oliver; A. Van Etten, Richard

doi:10.3324/haematol.2016.152710

Public

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

Published in Haematologica • Dec 7, 2016

Authors:

Jörge E. Cortes

Moshe Talpaz

Hedy Smith

Abstract

A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5′-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL1 and FLT3 and may be active against resistant mutat...

Subject

Myeloid leukemia

Medicine

Pharmacodynamics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!